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Successful Islet Allotransplantation in Diabetic Rats Immunosuppressed 
With FKS06: A Functional and Immunological Study 
W.J. Tze, J. Tal. 5.S.C. Cheung, N. Murase. and T.E. Starzl 
The eHect of II novel immuoMUppressive agent, FK506, on fresh iKl~t allografts WIS evaluated In diabetic rats across major 
Ilistocompatlbility complex (MHC) barriers with respect to the transplantation (TR) site, Islet SOllrce, treatment regimen, and 
antidonor antibody (Ab) titen of the recipients after fR. The functional periods of Wistar (Wi) islets transplanted under kidney 
capsule IKe] or intraportally (IPo) and of a mixture of Wi and Lewis (I.e) islets under KC or IPo In nonimmunOluppressed ACI rat 
",Ciplents were 6.9 :I: 0.4 In = 7),6.4;t: 0.5 In = 7), S.6 !t 0.4 In = 71, and 6.2 :t 0.4 In = Ii) days, respectively. FI<5OI treatment at 1 
rng/kg/d intramu=>cularly 11M) for 2 weeks (protocol I) follOwing islet 1R under KC and IPo slgnificently prQJongad the allograft 
function to mo.e than 71.8 :t: 11.3(n == 10) and 161.7:t: 18.5 In .. 11) days, respectively. Additional treatment with FK506 at 1 
mg/kg/wk (protocol III further Increased the islet survival under KC to more than 212.6 :t: 22.3 In .. 8) days. With this FKII06 
treetment protocol, the Wi -I- Le mixed-islet allograft func:tion WIS extended to more then 106.1 ± 10.6 (n = 7) and 167.9 = 28.6 (" = 71 days und.r KC .nd IPo ..... pectiv.ly. Nephrltltomy In 8/8 ACt rats with long-term-funcdonlng WI (n = 61 and Wi + 18 
(n = Z) Islet allografts resulted In their retum to hyperglvcemia. Immunohistochemical staining shovwd abundant ipsulln. 
politive cells .Uhe graft site, with small numbers of CD4- and CDS-positive cells present in the vicinity of the normal-appearing 
islets. Macrophag85 w .... not detected. The ImmunoBuppressive effect of FK50G _ further tested In ACI rats pr •• ensiti~ed bv 
a previous Wi islet TR. When the duration between the first and second TR under KC _.114.3 :t: ZO.5 dap. protocol II 
treatment significantly prolonged the graft function to more tIlan 152.9 :t 28.7 In = 8) days. However. with a short duration of 
about 2 weeks between the two TRs, the same FK506 protocol achieved Islet graft ful1G1ion of 14.0 :t 3.8 days In = 71. Additional 
immunosuppression with cyclophosphamide did not further Improve the survival time. Antidonor Ahs detected in ACI 
recipients of Wi islet allografts w.re slgnHicantly lower 1n the FK501J.treated animals compared with the nontrwlltmen1: group. 
WI and La skin grafts performad in three ACt rats with long-term-functioning Wi islets IPo caused the rejection of the Islet 
aJlografts. Skin grafts were also rejected' in the first-set fashion. Six ACt recipients with long.term-fuoctioning IPo WI islet 
aUografts were rendered hypergl-,.;emic; by 5treptolocln ISTZ) in/ectlon. Long-term normoulveemia without lurttt ... FK606 
Immunosuppression was ac:hieved following r.transplantation with fresh Wi ialm Po In = 2), but not under KC In = 2). The 
results of the present IitUdY Indicate that FK508 w. an effective Immunosuppressant (or Islet allotra.plantatlon in diabetic; 
ACI rats ecross MHC barriers with blets from two donor strains. IS wen as In sensitized recipients whose antidonor activitte. 
had subsided. Th. efficacy of the Immunoluppreselon WIIS influenced by the FK506 treatment protocol and the site of the Islet 
transplant. The results suggest that Fl(506 could be ueeful in clinical islet TR. 
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I SLET TRANSPLANTATION (TR) has been shown to 
restore normoglycemia and prevent the development of 
chronic complications in diabetic animals.I,z The applica-
., tion of allotransplantation and xenotransplantation of pan-
creatic islets for the trcauncnt of diabetes is hindered by 
immune rejection. FK506. a new immunosuppressant, has 
been demonstrated to be many times more potent than 
cydosporin A in the suppression of milted leukocyte reac-
tion in vitro.3 We have earlier shown that FK506 was an 
effective immunosuppressive agent for fresh islet allograft 
across the major histocompatibility complex (MHC) bar-
rier.' The efficacy of FK506 in the prolongation of islet 
allograft survival has been found to be influenced by the 
dosage of FK506 and the: site of the islet graft.4.S The 
present study was undertaken to determine whether FKS06 
was effective in the prolongation of fresh islet allograft in 
sensitized diabetic rat recipients and in recipients of islets 
from one or two donor strains in two commonly used TR 
sites (kidney capsule [KC} and intraportal [IPo]). The 
immunologic status, including the possibility of tolerance 
induction, in recipients with long-term islet allograft func· 
tion was also investigated. 
MATERIALS AND METHODS 
Animals 
Male rats of outl>red Wistar (Wi) and inbred iewi~ (Le) 5fr.Iim 
(ItTl') with body weight; of 350 to SOO g were used as donors of 
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pancreatic tissue, and rats of inbred ACI (RTI") strain were used 
as streplozocin (STZ)·inducc:d (55 mg/kg IV) diabetic recipients 
(Harlan-Sprague-Dawley. Indianapolis, IN). An animal was de· 
tined as diabetic only when the serum glucose level was greater 
than 400 mgi dL for more than 10 days. 
Isk!1 Isolation and TR 
PancreatIc tissue was digested with collagenase. and tile Islels 
were hand·picked under I di&scction microscope. Cantamiaating 
acinar tissues and blood vessels were removed from the islets by the 
slngle·layer Hypaque·FicoJI (H-P) separation technique.b For KC 
TR, approximately 2,000 fresllly isolated isJCl$ suspended In a total 
volume of 70 p.L Hanka balanced salt solution (HBSS) wen: 
injected. For IPo TR. the islets were suspended in 200 pI. HBSS in 
II Monojea U100 Insulin synnge (Sherwood Medical, 5t louis. 
MO) and injected over a l-minute period into diabetic recipients. 
The syringe was flushed twice with the recipients' blood. 
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Immunomppressicn Protocol 
The injec:tablc form of FK5[J6 (lot no. 116393) was provided by 
Fujisawa Pharmaceutical (Osaka, Japan). The required amount of 
the mmpound was weighed out daily and prepared in saliM within 
10 minutes of Intramuscular (lM) injection. The administration of 
FKS06 was initiated on the day of TR. Protocol I consisted of 
FKS06 at 1 mg/qJd 1M for:Z weeki. Protocol D coll8isted ofFKS06 
1M administration at 1 ma/kg/d for 2 weeks followed by 1 
mg/kg/wk. ProtocollII consisted of FKS06 1M administration at 1 
mg/kg/d for 2 weeks followed by 1 rna/kg/wI: plus cyclophospha-
mide at 20 mglkg/d 0[1 days -1,0, and +1. 
Assmment of Graft Function 
Daily serum glucose levels and body weights of recipient rars 
were determined for 2 weakl after TR and then twice weekly 
thereafter. Rejection was coJlSidered to have oc:curred when the 
serum glucose IC'lCI ellCCCded 200 mgldL on 3 suQlCSSive days. 
SuMliwi time for each recipient sroup i, ",ported as the mean == 
standard e11'Ol" of the mean. Statistical evaiuation was performed by 
the Mann-Whitney Utest. Apnlue of le55 than .OS was considered 
statistically significant. 
An Intravenous glucose tolerance test (IVGTI). 1 ,/kg IV 
throup the femoral vein in ovcmlght..fasted animal&, was per-
formed in some Islet recipients 1 weele after ehe last dole of PKS06. 
Blood samples were collected from the tan at 0. 1.3, S. 15.30.60. 
90, and 120 minutes for glucose determination. 
Assessment of the EJflcacy 0{ FKS061mmunosuppression 
on Islet AllOflTtlft Survil'Qlln Sensitized RecipietllS 
Diabetic ACI rats were transplanted with C",sh Wi islets under 
the left KC. After rejection or tile first islet allograft. a second Islet 
gra£1 frum the SlIme elonor lItrain was performed in the contraiat-
eral kidney of the recipienL The second TR was performed either Il 
short or long perlud after the lint TR. The animals were treated 
with FKS06 os indicllted. 
Antibody Studies 
Collected sern were stored at -2O"C and heated at S6·C for 30 
minutes before antibody (Ab) determination. Cytotoxic Ab levels 
in the ACI recipients of flab Wi b1cts with and wldlout ro06 
treatment were dctcnnincd using pooled Wi strain splcnoc:ytcs lUI 
talget ceUs and rabbit serum as tile complement source (Low·Tox 
R complement. Ccdarlanc Laboratory. Hornby, Ontario, Canada). 
Ab titer is defined as the reciprocal of serum dRuwa that IdIIs 50% 
of the target cells by trypan blue dye exclusion uuy.7 
AuelSntem otTolera,," 
To U&eSS tbe possibility of toleranc:e in rats With lona·tcnn-
functioning Wi islet allografts. Wi and Lc akin grafts wm; im· 
planted in the lateral thoracic resJoa oftke ACI recipient. SUJVivat 
of the Islet and sldn arafts WIlre monlto",d. In addition, six rats with 
long-tcrm-func:tionin8 islet 1Il1opaft. were JCnderecl diabetic: with 
STZ at 3S mg/kg. After LO days of bypergIycemia. retransplanta-
lion offllllh Wi islets IPu or undor KC was perfonned in tbelie rats. 
The recipients did no' receive any rurther FKS06 ,",alment. Serum 
Jlucose level was monitored 8S an indicator of islet allograft 
function. 
lmmunohistochemiall Studies 
Some func:tional grafts we", remOVlld for immunohistochemical 
stainings. Paraffin sections ware stainad ror IIl8u1in and Slucagan 
witb Immul1operoxidase staining (ABC Stalning Kits, Vectastaln, 
Dimell8ion Laboratol)'. Miasit&eup. Ontario. Canada). Frozen 
sections were stained with monoclonal Abs for leukocyte common 
andgens, class II antigens, CDS and CD4 lymphocyte SUbsets, and 
macrophagu (Ceclarlatltl Laboratoty). 
RESULTS 
Table 1 shows the functional period of Wi and admixed 
Wi and I.e islet allograft survival in two TR sites in diabetic 
ACI rats treated with two different FKS06 protocols. FKS06 
protocol I treatment significantly prolonged the survival of 
islet allograft transplanted both under KC and IPo. The 
survival was significancly longer in the [Po site than in KC 
(group 7 " S, 11 of 11 " three of 10 functioned for> 110 
days).ln the lCecile, the islet sUn/wal for recipients troaled 
with FKS06 for 2 weeks was more than 7l.8 ~ 11.3 days 
(group S), and this increased significantly to more than 
212.6 ± 22.3 days (group 6) when nn additicmal weekly 
injection of FKS06 was given. In the groups trangplunled 
with a mixture of Wi and Le islets, FKS06 trcatmcllt 
signiticantly improved the islat allograft functional period 
over that of tbe untreated recipients (group 8 v 3). Also, the 
group transplanted IPo had a longer functional period of 
the mixed Wi and I.e allografts than the group transplanted 
Tabl.l. l'unl:1lCJnal Period of WI alld AdmIlCture of WI .1Id I.e 111ft AllograftS in Diabetic ACI RatllmmunOlupprusld With FK50II 
FIC506 
Group Donor She T, .. vnenl't n Oe,_ 
I WI KC No 7 5,1$,7.7.7,8.8 
2 Wi IPo No 7 5.5.6.6.7.8.8 
3 Wi+le KC No 7 4,5,5.5.6.7,7 
4 WILe IPo No 5 5.'.6,7,7 
6 Wi KC I 10 41.45.46.47,48.52,73, > 1OM1~ > 122-. > 124" 
6 WI I(C II 8 > 112-,:> 114-• > 212-, > 245, > 251,:> 252.:> 255,:> 260-
7 WI IPo II 2x 11ot.4x > 122t. > 167*, > 191*,> 193*, > 210, > 31011 
8 Wi+Le I(C II 7 67.85,90-,103,120·,132,>145 
9 Wi+LB IPo II 7 9~K1MOI 110,120.240, > 252,>263 
"Nephrectomy. 
tProtocoll, FK506 at 1 mgllcg/d for 2_ekl 1M: protocol h, F1t506 at 1 mg/kg/d for 2 _k. + _eklv 1M. 
:!=SkIn graft. 
ISTZ,3S mg/kg IV. 
!pied of anesthesia. 
,. 
Me ... .:tSEM 
C!.II:!: 0.40 
6.4;!: 0.48 
5_6 :t 0.43 
6.2 ::!: 0.37 
>71.8:!: 11.3 
>212.6 :I: 22.3 
> lln.7 j: 18.6 
> IOU:!: 10.5 
> 167.9 :I: 28.8 
"1 
l-
:t1 
h 
h 
~­
Ii. 
'11 
'al 
,)0 
on, 
.:n 
1111 
lid 
\!d 
lic 
06 
(If 
'he 
(C 
10 
eel 
l~D 
.an 
kly 
led 
::nt 
iod 
the 
! of 
ted 
7 
3 
3 
Iii 
5 
& 
FALK LIBRARY (PIT) 
EFFECT OF FK506 ON FRESH ISLET ALLOGRAFT .. 
under the KC (group 8 v 9). However, FlG06 efficacy was 
lower for mixed islet allogrdft than for islcts from a single 
donor strain in the KC but not IPo (group 6 v 8, P < .01; 7 v 
9, NS). 
Glucose metabulism was improved in AO rats with 
functioning Wi islctJ;. The glucose clearance (K) Tales of 
IVGTfs performed in ACI recipients with functional Wi 
islets undcr KC 1 week aftcr the last Injection of FK500 
were 2.16 :t 0.09 (group 5, n = 6) and 1.83 :t 0.06 (group 6, 
Jl = 7), which were much improved over rates of the 
diabetic controls (K rate < 1.0) but significantly lower than 
those of nonnal control animals (K = 3.10 :t 0.11, n = 11). 
To confinn that the long-term normalization of blood 
glucose levels in ACI ruts with Wi islets was not due to 
spontaneous reversion of diabetes. graft removal was per-
formed in some animals. Nephrectomy of the graft-
containing kidnL'Y resulted in the return to hyperglyccmia in 
six out of six cases of ACI rats with Wi and two out of two 
with Wi + Lc isle\ allografts. Wi islet allograft with 
normal-appearing histology was observed under the KC 114 
days after TR in diabelic ACl rats immunosuppres,'lCd with 
. protocol II. Insulin-comalning i:;letll were abundant. In 
some areas of the gnlft, small numhefll of CD4-positive and 
CDS'positive cells were moro prevalent. Staining for macro-
phage with monoclonal clones OX41 and OX42 and al~o 
with nonspecific esterase IItaining failed to detect them at 
the graft site. Normal.appearing islets were also present in 
the graft area from diabelic recipient rals subjected to 
FKS06 Prol(1Col 1. However, more oggregatcs of CD4-
positive and CDB-positive: eclls were prescnt adjacent to the 
islets than observed in the previous group. 
Figure 1 shows the scrum glucose levels in six ACI 
Fig 1. Serum glucose levele 
of AQ rats with long-term-func· 
tlonellPo WI b;1~ aUognrf1s reno 
dered diabetic bV SlZ ilIje&:tlon 
~w} w then either "traM-
planted with fresh WI Islet. ,Po 
rv • .01 QJ' &ladtn' I(C (Cl. t>), or 
without retranspllntatlon (0. <1\. 
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recipient rats with long·tcnn-funetional Wi (Po allograft 
(Table 1, group 7) reinduced to become diabetic by STZ. 
Retransplantation of two of these animals with fresh Wi 
islets IPo resulted In prolonged normoglycemia of the 
recipients without further FK506 immunosuppression. One 
rat died of surgical complications 30 days after retransplan· 
talion, with functional islet allograft at death. In the second 
animal, a Wi skin graft performed at day 90 resulted in its 
return to hyperglycemia in 9 days. In contrast, the two 
animals that received the rctramplantation of fresh islet 
allograft under the KC rejected the grafts in 5 and 8 days. 
Two rats without retransplantation remained hyperglyce-
mic. 
The Wi rat islets that functioned long·tcrm IPo In 
diabetic ACI rats still retained their antigenicity. Wi strain 
skin graft performed in these animals induced islet graft 
rejection in three out of three cases between 9 and 13 days. 
Both Wi and the third-party Le skin grafts were rejected in 
the fint-sct fasbion in 12 to 13 days. 
P.05 
Table 2 shows the efficacy ofPKS06 protoooill treatment 
on islet allograflllurvival in diabelicACI recipients that had 
rejected it Wi islet graft performcd SO to 177 days previ-
ously. The immunosuppression was effective in achieving 
long· term survival in all eight recipients, with three out of 
eight recipients lIehieving indefinite graft survival. This was 
not si,nificantiy different from that achieved in nonsensi-
t!zed animals (Table 2 group 3 v Table 1 group 6, P == .10). 
In contrast, when the interval between the lint and second 
TR was ofshortcr duration, ie, 2 weeks, FKS06 immunosup-
pression alone (group 4) and in combination with cyclophOS-
phamide (group 5) was found to be Ineffective, with only 
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Tlble Z. £ffKt of FKSQI Trutment on FunatlDnBl Islat AIIagrllft SlI'VIval Undlll'lCC In PnsIHlBitlud ACI Rata 
Deyt FICSOI 
G-wp Donor '_2ndT, T_ n 0.,. Mlan:tSEM 
WI No No 6 5.5.6,6,7.1 6.0:1: 0.31 
2 WI 108.3 :t.US No 8 6,7,7,7JJ.8 7.17:1: 0.31 
3 \/IIi ',4.3:1: 20.& II 8 59,78,99,113,> 145,201,> 258,>270 > 152.9 :I: 28.7 
4 WI 15,3:!: 0.3 II 7 &,5.10.' 1.14, 1D,34 14.0:1: 3.. 
5 Wi 14.20:t Q.5 .1 6 8, 10,18,19,21 14.8;!; 2.5 
NOTE. sensitization wal achievad by frash WI islet allograft unclar ICC. 
·Protocol •• FX!SOe It mg/lcg/d for 2 waeQ + weekI!( 1M; protocol UI. FK50S at 1 mg/kg/d fDr2weekl + weeldylMi cyclophosphamide 1 mg/kgfd. 
one recipient having a prolongc:d functional graft. Neverthe-
less, hyperacute rejection WjlS not observed. 
Figure 2 shows that in ACI rats without FKS06 immuno-
suppression, anti-islet donor Ab titers increased rapidly 
and peaked at day 14 at 77.3 :!:: 0.9 (n = 12, mean ± SEM). 
In comparison, tbe and-Wi Ab titers were significantly 
lower in islet allograft recipients heated with FKS06, with 
the peak titer at 11.1 ± 2.4 (n - 7) on day 7. The anti-Wi 
Ab was negligible In the recipients at the time of the second 
TR when the inte1'V81 between the fitst and second TR was 
more than SO days In sensitized recipients. The peak Ab 
titers remained low at 8.0 :t 2.2 (n :: S) after the TR while 
immunosuppressed with FK506. In comparison, 10 the 
recipients that had recently rejeeted the first Wi islet 
allograft, anti-Wi Ab titers were high, with a mean of 115 ;I: 
12.8 (n = 5). and increased further to S120n day 8 after the 
second TR despite FKS06 immunosuppression. 
DISCUSSION 
Results of the present study show that FKS06 was an 
effective immunosuppressant in prolonging fresh islet allo-
graft survival across the MHC barrier. At a daily dosage of 1 
mg{kg administered 1M for 14 days starting on the day of 
TR, signifiatDt prolongation of fresh Wi islet allograft 
survival was observed both under the KC and IPo. 111e 
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Fig 2. Mean cytotDxlc Ab titers In AQ reclp~ of n.h Wlillet 
allooraft undar KC with I .. __ :I: SEM, n -71 .IId without 10. 
n = 121 FKIIIII treltment. 
effieacy of PKS06 treatment was improved by additional 
weekly treatment in the group with islets transplanted 
under KC. This treatment regimen was also effective ill 
prolonging the survival of islet allograft c:ompo&ed of tissues 
from two donor strains. The obselVation may be of some 
importance, since most studies show that islet tissue from 
more than one donor Is needed to reverse the diabetic state 
of the recipients in clinic:a1 TR. despite a recent report 
showing successful cUnlcal islet allotransplantation with 
islets procured from a single donor.a.I. Although FlG06 
prolonged islet anograft survival from single- and two-
donor strains transplanted under KC, the result achieved in :§ 
the former group was significantly better. One possible 
explanation is the higher immunogenieity of the miltcd-islet 
preparation. 
Earlier. Yasunami et als failed to achieve prolonged islet 
allograft survival under KC. This difference could be due to 
the lower dosage of FKS06 administered for a shorter 
period than In the present study. The route ofTR seems to 
be important. since we observed the superiority of the IPo 
over the KC site in the islet TR model. This confirmll 
prcvious observations.' The suggestion that FKS()) is me-
laboliied extensivoly in the livor before I!xcretion may 
contribute to the superiority of the IPo site. I I 
Despite voluminous litcruture on the effect 01 various 
immunosuppJ'CMivo agents and islet pretreatment prolo-
0011 on islet sUlVival in nonscnsitizcd animals, relatively 
little information is a""ilable for sansitized animals. The 
data demonstrated that FK506 was effective in prolonging 
the second Islet allograft survival in sensitized raL'!, pro-
vided the antidonor immune activities had subsided. 
Our results would indicate that the classic form of 
tolerance was absent in rats with long-term islet allograft 
function. as they railed to retain the donor-strain skin graft. 
Furthermore, the retransplanted islets were susceptible to 
induction of rejection by dOllOr-straln skin graft, However, 
some form of tolerance: was present in these animals, since 
retransplantation of fresh donor-strain islets IPo following 
the destruction of the islet graft with STZ resulted in 
prolonged normoglycemia without further FKS06 immuno-
sUpptCSsion. This observation is therefore similar to tbat of 
Kamei and Yasunami. who observed a similar tolcrancc 
state induced in their rats with cydosporin A treatmenL 1% 
Ricordi et al13 have provided oxperimental evidence that 
the function of human islets residing underneath the KC of 
nude mice is deleteriously affected by the administration of 
FKS06 at doses of I mg/kg/d and higher. In addition. 
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EFFECT OF FK606 ON FRESH ISLET ALLOGRAr.T 
FKS06 has been shown to be diabetogenic in intact nontruns-
planted animals.14.15 This effect OD carbohydrate metabo-
lism is reversible following the discontinuation or dose 
reduction of the medication. Furthermore, FK506 has been 
used in clinical t'ilct allotransplantation with mixed re-
5ults.16 
In conclusion, PKS06 iB a potent, effective immunosup-
pressant for islet allograft TR in diabetic rats across the 
MHC barrier. The immunosuppressive effect was observed 
in recipIents or islets from more than one donor strain and 
in presensitized recipients. In the sensitized recipients. the 
FAX NO. 64B9020 P.07 
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long inleN!!1 between the initial TR and retransplantalion 
was crucial to the survival of the second transplant using 
FK506 as the anti rejection agent. The results of this study 
would provide useful information for clinical islet TR. 
Improvement of the treatment regimen using FK506 should 
minimize the side effects, and allow it to become useful in 
clinical i:r;let TR. 
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